INSIGHT 2: A phase II study of tepotinib plus osimertinib in MET-Amplified NSCLC and first-line osimertinib resistance

Egbert F. Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M. Tho, Xiuning Le, Julien Mazieres, How S Hin, Masahire Morise, Viola W. Zhu, Daniel Tan, Kristina H Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M. Schumacher, Niki Karachaliou, Yi Long Wu

Research output: Contribution to journal › Article › peer-review